Previous 10 | Next 10 |
PALISADES ANNOUNCES NEW FOUND MAKES NEW HIGH-GRADE, AT SURFACE DISCOVERY AT JACKPOT ZONE AT QUEENSWAY PROJECT Canada NewsWire VANCOUVER, BC , June 22, 2023 /CNW/ - Palisades Goldcorp Ltd. (TSX-V: PALI) (" Palisades " or the " Company ") is pleased to anno...
Live webcast fireside chat on Thursday, June 22 nd at 11:30 AM ET Carlsbad, CA, June 14, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) compl...
2023-06-01 09:24:33 ET Palisade Bio ( NASDAQ: PALI ) has named J.D. Finley its chief executive officer, the company said on Thursday. Finley had been serving as interim CEO since October 2022. Press Release . For further details see: Palisade...
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley h...
2023-05-24 12:39:00 ET Are you new to penny stocks? Do you want to know how to use momentum and stock market volatility to your advantage? In many instances, there are hidden opportunities with low-priced stocks, and savvy traders seek to uncover the next big winners. In this article, we wi...
Company approaching Phase 2 t opline dat a readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing d ose optimization study with 25 % enrollment complete Carlsbad, CA, May 24, 202...
PALISADES ANNOUNCES NEW FOUND GOLD INTERCEPTS AT KEATS WEST Canada NewsWire VANCOUVER, BC , May 17, 2023 /CNW/ - Palisades Goldcorp Ltd. (TSXV: PALI) (" Palisades " or the " Company ") is pleased to announce that New Found Gold Corp. (" New Found "), ...
2023-05-12 09:31:52 ET Palisade Bio press release ( NASDAQ: PALI ): Q1 GAAP EPS of -$0.54. Revenue of $0.25M. As of March 31, 2023, the Company had cash and cash equivalents of $13.3 million, which was supplemented by gross proceeds of $6.0 million from a registered di...
Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapi...
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing effica cy Company expects enrollment to be completed in Q3 2023 Carlsbad, CA, May 11, 2023 (GLOBE...
News, Short Squeeze, Breakout and More Instantly...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition o...
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Ph...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...